Bernd R. Seizinger, a director at Aprea Therapeutics, Inc. (NASDAQ:APRE), recently purchased 10,000 shares of the company's common stock. The transaction, executed on October 11, 2024, was completed at a weighted average price of $2.68 per share, amounting to a total purchase value of $26,800. Following this acquisition, Seizinger holds a total of 44,730 shares in the company. The shares were bought in multiple transactions at prices ranging from $2.52 to $2.70.
InvestingPro Insights
The recent insider purchase by Bernd R. Seizinger at Aprea Therapeutics, Inc. (NASDAQ:APRE) comes at a time when the company's stock has faced significant headwinds. According to InvestingPro data, APRE's stock has experienced a substantial decline, with a 6-month price total return of -56.61% as of the latest available data. This insider buy could be seen as a vote of confidence in the company's future prospects, despite recent market challenges.
InvestingPro Tips highlight that Aprea Therapeutics holds more cash than debt on its balance sheet, which may provide some financial flexibility as the company navigates its current situation. However, the company is also quickly burning through cash, a factor that investors should consider when evaluating the stock's potential.
It's worth noting that analysts do not anticipate the company will be profitable this year, which aligns with the reported operating income margin of -1112.69% for the last twelve months. This underscores the challenges Aprea faces in achieving profitability in the near term.
For investors seeking a more comprehensive analysis, InvestingPro offers additional tips and insights that could provide a deeper understanding of Aprea Therapeutics' financial health and market position. There are 11 additional tips available on InvestingPro, which could offer valuable context to the recent insider purchase and the company's overall outlook.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.